Saturday 31 October 2026 Export ISRG’s income statement to Excel — free account

Intuitive Surgical, Inc.

ISRG Healthcare Medical Instruments & Supplies

Intuitive Surgical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.1 billion, up 20.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 25.5% and free cash flow grew 69.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for five consecutive years, operating cash flow growth for three.

432.55 16.21 −3.61%

Follow ISRG

Alert me

Market cap: $155.6B
P/E: 48.9×
Fwd P/E: 51.7×
Dividend yield: —
F-score: 7/9
Altman Z: 50.09
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Financial Analysis Segments Filings

Intuitive Surgical, Inc. (ISRG) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
Instruments and accessories	6,019	59.80%
Systems	2,474	24.58%
Service	1,572	15.62%
Gross margin		66.00%
Operating margin		29.27%
Pre-tax margin		32.90%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Service	1,572 15.62%	1,307 15.65%	1,168 16.39%	1,024 16.46%	916 16.05%	724 16.61%	724 16.17%	635 17.05%	573 18.26%	511 18.87%
Also reported: a second breakdown of the same revenue
Instruments and accessories	6,019 59.80%	5,079 60.81%	4,277 60.03%	3,518 56.54%	3,101 54.30%	2,456 56.34%	2,408 53.77%	1,962 52.68%	1,637 52.16%	1,396 51.57%
Systems	2,474 24.58%	1,966 23.54%	1,680 23.58%	1,680 27.00%	1,693 29.66%	1,179 27.05%	1,346 30.06%	1,127 30.26%	928 29.58%	800 29.56%
Service	—	—	—	—	—	—	724 16.17%	635 17.05%	573 18.26%	511 18.87%
Product	8,493	7,045	5,956	5,198	4,794	3,635	—	—	—	—
Revenue	10,065	8,352	7,124	6,222	5,710	4,358	4,479	3,724	3,138	2,707

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Product	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
da Vinci 5 systems	Q3 FY2026	315.00	240.00	+31.25%
da Vinci surgical system installed base	Q3 FY2026	12.1K	10.8K	+12.37%
da Vinci surgical system placements	Q3 FY2026	546.00	427.00	+27.87%
Ion endoluminal system installed base	Q3 FY2026	1.2K	954.00	+20.75%
Ion endoluminal systems	Q3 FY2026	56.00	50.00	+12.00%
Ion procedure volume	Q3 FY2026	31.0%	52.0%	—
Systems placed under operating lease arrangements	Q2 FY2026	254.00	193.00	+31.61%
Systems placed under usage-based operating lease arrangements	Q2 FY2026	131.00	124.00	+5.65%
Worldwide da Vinci procedures	Q3 FY2026	14.0%	19.0%	—
Worldwide procedures (da Vinci and Ion combined)	Q3 FY2026	15.0%	20.0%	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024
da Vinci 5 systems	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
da Vinci surgical system installed base	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
da Vinci surgical system placements	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Ion endoluminal system installed base	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Ion endoluminal systems	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Ion procedure volume	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Systems placed under operating lease arrangements	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Systems placed under usage-based operating lease arrangements	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Worldwide da Vinci procedures	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Worldwide procedures (da Vinci and Ion combined)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.